VIP (vasoactive intestinal peptide)
Availability Clinical trials only
What it is
Vasoactive intestinal peptide is a 28-amino-acid signaling molecule the body makes throughout the gut, lung, and nervous system. It relaxes smooth muscle, dilates vessels, and damps inflammatory signaling. The synthetic version, aviptadil, has been studied as a drug for decades; the wellness market knows it as a compounded nasal spray used in chronic inflammatory response protocols.
Why people take it
VIP receptors sit densely on the lung cells that severe inflammation destroys, which is why the compound keeps attracting serious research attention. In longevity clinics the draw is looser: a hope that a broadly anti-inflammatory signal helps with lingering post-illness symptoms, mold exposure, or unexplained fatigue.
How it's delivered
Aviptadil has been given intravenously and by nebulizer inside registered trials, including an NIH-funded COVID-19 program and an expanded-access protocol. Outside trials the only route in general use is an intranasal preparation from a compounding pharmacy on a prescriber's order. No form of VIP is FDA-approved for any indication.
Where the evidence stands
The most rigorous test VIP has faced is the COVID-19 program, and it did not clear the bar. The sponsor reported survival and recovery advantages, but FDA declined emergency use authorization in November 2021, citing insufficient data across only 131 randomized patients, and declined again in July 2022 for a subgroup defined after the fact. Trials in sarcoidosis and pulmonary hypertension remain early. For the chronic-inflammation protocols driving most consumer interest, the published evidence is smaller still, largely uncontrolled, and tied to one clinician's framework.
Estimated cost
- No approved product carries a list price
- Compounded nasal spray typically $80–$150/mo, quoted per pharmacy
- One national compounder lists it from about $10 per mL
- Telehealth programs observed charging up to $399/mo
- Not covered by insurance
Who offers it
No clinic or telehealth provider in our research pass listed VIP as a menu item. It reaches people through compounding pharmacies on individual prescriptions, or through enrollment in a registered trial.
Recorded from trial registries and the published record on our last research pass. We list no referral path to this compound and are not compensated for this entry.
Go deeper
No dedicated VIP guide yet. The Peptide Explorer entry carries the compound record, and the immune peptides guide covers how to weigh an inflammation-signaling peptide against the ones with outcome data.
Longevity.io is for educational purposes only and is not medical advice. Whether an investigational peptide belongs in a plan is a conversation for a clinician who knows the whole picture, including what has already been ruled out. Confirm any claim against the trial record itself.
Build your starting plan.
A few short questions, about two minutes. The Blueprint recommends where to start and explains why.
Build my Blueprint
